NovaSterilis was founded in 2000 to develop and commercialize the application of supercritical carbon dioxide (SCCO2) for use in sterilization of biomedical materials. Sterilization is defined as “elimination of all forms of microbial life, including endospores”. Contrast this to antiseptic which is defined as "the destruction of vegetative pathogens on living tissue."
Sterilization using SCCO2 involves lower temperatures (31°C) and pressure above 1100 psi. This lower temperature makes SCCO2 ideal for materials which are temperature sensitive or reactive with other forms of sterilization. SCCO2 can penetrate and sterilize delicate products and materials, such as allograft tissue, without damage to the product's structural or chemical integrity.
The Nova2200™ commercial sterilizer utilizes NovaSterilis' patented technology to provide a state-of-the-art, gentle sterilization for different types of musculo-skeletal tissues such as bone, tendon, skin and other types of tissue. The Nova2200™ process achieves a Sterility Assurance Level of 10-6 (SAL6) while maintaining the biomechanical properties and quality of the allograft. The larger Nova8800™ commercial sterilizer is capable of sterilizing larger samples. It has an 80 liter vessel and is four times larger than the Nova2200™.
NovaSterilis is seeking committed partners to expand the commercial applications of its patented technology. Potential applications for our technology include, but are not limited to pharmaceuticals, biologics, vaccines, engineered tissues, medical instruments, devices and implants.